Investment Rating - The report maintains a "Buy" rating for Kelun Biotech [2][16] Core Insights - Kelun Biotech reported a revenue of RMB 2.06 billion for 2025, representing a year-on-year growth of 6.5%, with a net loss of RMB 382 million, which is an increase of 43.2% year-on-year [5][12] - The adjusted net loss for 2025 was RMB 211 million, reflecting a year-on-year increase of 78.3%, aligning with expectations [5][12] - The company achieved product sales of RMB 543 million in 2025, a significant increase of 949.8% year-on-year, while revenue from business development collaborations decreased by 19.6% to RMB 1.50 billion [5][12] - R&D expenses rose by 9.4% to RMB 1.32 billion, and selling expenses surged by 160.1% to RMB 475 million, resulting in a selling expense ratio of 23.1% [5][12] Financial Data and Profit Forecast - The company expects revenue growth to continue, with projected revenues of RMB 2.70 billion in 2026, RMB 4.80 billion in 2027, and RMB 6.47 billion in 2028, reflecting growth rates of 31.25%, 77.64%, and 34.74% respectively [10][18] - The forecasted net profit for 2026 is a loss of RMB 132 million, with a turnaround expected in 2027 with a profit of RMB 528 million and RMB 1.54 billion in 2028 [10][18] - The earnings per share (EPS) forecast for 2026 is adjusted to a loss of RMB 0.57, with a projected profit of RMB 2.26 in 2027 and RMB 6.61 in 2028 [10][16] Product Pipeline and Market Position - Kelun Biotech has four commercialized products, including Sac-TMT, which is expected to see significant sales growth due to its inclusion in the National Reimbursement Drug List (NRDL) [6][13] - The company has initiated multiple pivotal clinical trials for Sac-TMT, targeting various cancers, and has received NMPA approval for its use in specific indications [7][14] - The pipeline includes a rich array of oncology and non-oncology products, with several in different stages of clinical trials, indicating a strong focus on innovation and market expansion [8][15]
科伦博泰生物-B（06990）：核心管线Sac-TMT海外进展积极